• Evaxion developed a genetic adjuvant know-how that enhances the immune responses of viral, bacterial and most cancers vaccines
• Preclinically validated for each DNA and mRNA vaccines, and prepared for medical testing  
• Anticipated massive market potential for DNA and mRNA vaccines in opposition to most cancers, viral and bacterial illnesses

COPENHAGEN, Denmark, Might 25, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Firm”), a clinical-stage biotechnology firm specializing within the discovery and growth of AI-powered immunotherapies, immediately unveils the know-how behind its novel, proprietary genetic adjuvant developed to boost the effectiveness of DNA and mRNA vaccines for infectious illnesses and most cancers. 

Newest knowledge from the adjuvant program have been introduced at Evaxion’s reside stream R&D Day, Might 25, 2023. 

“We’re excited to current this novel genetic adjuvant know-how to the worldwide scientific group. It boosts Evaxion´s personal DNA know-how and has the potential to enhance the impact of nearly any vaccine. We foresee an important market potential in that this know-how seems to be extremely efficient in each DNA and mRNA based mostly vaccines in opposition to most cancers in addition to infectious illnesses,” stated Per Norlén, CEO at Evaxion. 

Evaxion´s novel genetic adjuvant carries the code for CCL19, a molecule recognized to draw immune cells, notably antigen presenting cells, and will be encoded into both DNA or mRNA vaccines with the intention of boosting the immune response. 

Newest knowledge present that the genetic adjuvant know-how boosts the antitumor impact in preclinical tumor fashions, and induces neutralizing antibodies and T-cell responses in opposition to each viral and bacterial antigens: 

Per Norlén continues, “By encoding the immune-stimulating molecule CCL19 into both DNA or mRNA vaccines, now we have demonstrated vital enhancement of the vaccines effectiveness. We imagine that this development holds immense potential for vaccine growth, because it boosts each B cell and T cell immune responses, making it relevant to a variety of vaccines. Constructing on the encouraging preclinical outcomes, the following step is to validate the know-how in sufferers.” 

Evaxion goals to convey the genetic adjuvant know-how into medical trials later this 12 months as a part of the personalised most cancers immunotherapy program EVX-03.  

Please go to the Buyers part of Evaxion’s web site to entry a replay of the R&D Day displays. 

About Evaxion

Evaxion Biotech A/S is a pioneering firm creating AI-powered immunotherapies. Evaxion’s proprietary and scalable AI applied sciences decode the human immune system to find and develop novel immunotherapies for most cancers, bacterial illnesses, and viral infections. Evaxion has a broad pipeline of candidates, together with three personalised most cancers immunotherapies. It’s positioned in Hørsholm, Denmark, with 50 workers listed on the Nasdaq New York inventory trade. For extra data, please go to www.evaxion-biotech.com.

Ahead-looking assertion 
This announcement incorporates forward-looking statements throughout the that means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Trade Act of 1934, as amended. The phrases “goal,” “imagine,” “count on,” “hope,” “intention,” “intend,” “might,” “may,” “anticipate,” “ponder,” “proceed,” “estimate,” “plan,” “potential,” “predict,” “challenge,” “will,” “can have,” “possible,” “ought to,” “would,” “might,” and different phrases and phrases of comparable that means establish forward-looking statements. Precise outcomes might differ materially from these indicated by such forward-looking statements because of numerous elements, together with, however not restricted to, dangers associated to: our monetary situation and want for extra capital; our growth work; price and success of our product growth actions and preclinical and medical trials; commercializing any permitted pharmaceutical product developed utilizing our AI platform know-how, together with the speed and diploma of market acceptance of our product candidates; our dependence on third events together with for conduct of medical testing and product manufacture; our lack of ability to enter into partnerships; authorities regulation; safety of our mental property rights; worker issues and managing progress; our ADSs and odd shares, the affect of worldwide financial, political, authorized, compliance, social and enterprise elements, together with inflation, and the consequences on our enterprise from the worldwide COVID-19 pandemic and the continued battle within the area surrounding Ukraine and Russia; and different uncertainties affecting our enterprise operations and monetary situation. For an extra dialogue of those dangers, please discuss with the danger elements included in our most up-to-date Annual Report on Kind 20-F and different filings with the U.S. Securities and Trade Fee (SEC), which can be found at www.sec.gov. We don’t assume any obligation to replace any forward-looking statements besides as required by regulation.